Abivax updates on ABX464 study to treat HIV

* Novel approach to treat HIV demonstrates safety and preliminary anti-viral activity in phase IIa

* Second phase IIa study to evaluate lasting viral control with ABX464 planned

Read more here 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here